Drugmaker Pfizer has swung to a fourth-quarter financial loss, instead of a modest profit, as a result of a just-announced charge to settle a long-running federal case over reimbursements for its former blockbuster heartburn pill.
Pfizer, which is planning a mega-acquisition of Irish drugmaker Allergan meant to reduce Pfizer's corporate tax bill, said on Tuesday that it has a tentative agreement to pay the federal government $US784.6 million ($A1.11 billion).
That would resolve litigation over the calculation of rebates Wyeth paid the government for Medicaid purchases of its severe heartburn treatment, Protonix.
The agreement must be approved by US District Judge Douglas P. Woodlock in Massachusetts, Pfizer said.
Pfizer, the largest US-based drugmaker, said it is charging the payment to its fourth-quarter results, which it restated on Tuesday.
That left the New York-based company with a loss of $US172 million, or 3 cents per share, in the last quarter, compared with a net profit of $US613 million, or 10 cents per share, initially reported on February 2.
For all of 2015, Pfizer is now reporting net income of $US6.96 billion, or $1.11 per share, down from the $US7.75 billion, or $1.24 per share, reported two weeks ago.
Pfizer said its adjust results for the quarter will not change.
Protonix heals acid reflux damage to the oesophagus. Cheaper generic versions of the drug, known as pantoprazole, came on the market about five years ago and around a dozen are available.
The settlement would resolve cases pending in the federal court that centred on Wyeth's practices related to rebates on Protonix sales between 2001 and 2006, when its patent, and market exclusivity, were still in force.
Pfizer bought the Wyeth company in 2009.
Wyeth is not admitting any liability, which is typical in the many settlements drugmakers reach with federal prosecutors for allegedly overcharging government health programs and other misconduct.
A few years ago, Pfizer paid $US55 million to resolve allegations that Wyeth promoted Protonix for uses not approved by the Food and Drug Administration.
Pfizer expects to wrap up its $US160 billion purchase of Allergan in the second half of this year, then move Pfizer's official headquarters for tax purposes from New York to Allergan's base in Dublin.
The strategy, called a tax inversion, would sharply decrease Pfizer's tax bill from its current US tax rates, though the drugmaker's operational headquarters would remain in New York.
Share
